| 1 |
Review Ornidazole-induced liver damage: report of three cases and review of the literature. 2003
Tabak F, Ozaras R, Erzin Y, Celik AF, Ozbay G, Senturk H. · Cerrahpasa Medical Faculty, Department of Infectious Diseases and Clinical Microbiology, Istanbul University, Cerrahpasa, Istanbul, Turkey. · Liver Int. · Pubmed #14708896 No free full text.
Abstract: Metronidazole and ornidazole, synthetic nitroimidazole derivatives, are used in the treatment of infections caused by anaerobic bacteria and protozoa. The drugs are well tolerated and serious side effects are very rarely encountered. Hepatotoxicity is a rare side effect and hitherto only six cases have been reported. We describe three patients who developed hepatitis after ornidazole use and review the previously reported cases. All three cases used ornidazole in conventional doses and developed hepatitis and associated cholestasis. They improved 1-2 months after discontinuation. We concluded that nitroimidazole derivatives may cause hepatotoxic damage resembling acute cholestatic hepatitis. Early recognition and withdrawal of the drug may prevent further damage.
|
| 2 |
Article Simultaneous presentation of hepatocellular carcinoma in identical twin brothers. 2002
Demir G, Belentepe S, Ozguroglu M, Celik AF, Sayhan N, Tekin S, Mandel NM, Buyukunal E, Serdengecti S. · Medical Oncology Department, Cerrahpasa Medical School, University of Istanbul, Turkey. · Med Oncol. · Pubmed #12180479 No free full text.
Abstract: Family history and hepatitis B virus (HBV) infection have been identified as risk factors for hepatocellular carcinoma. We report hepatocellular carcinoma (HCC) diagnosed at the same time in identical twin brothers. Serological analyses of the patients showed that both were chronically infected with HBV. Molecular analyses of the tumor specimens confirmed loss of heterozygocity of the Rb gene region. Both of the patients were unresponsive to chemotherapy and died within the same month with an interval of I wk. With a review of the current literature, we discuss the role of HBV infection and genetic factors on hepatic carcinogenesis.
|
| 3 |
Article Follow-up of a patient with chronic hepatitis C-associated cryoglobulinemia during four and a half years of maintenance interferon treatment. 2001
Celik AF, Ozaras R, Ozbay G. · Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey. · J Clin Gastroenterol. · Pubmed #11588550 No free full text.
Abstract: In this report, we present a patient with chronic hepatitis C-associated cryoglobulinemia who was kept on maintenance interferon treatment because of flare-ups in cryoglobulinemia-associated signs and hepatitis after withdrawal, dose reduction, and increase in dose intervals of interferon. This type of interferon use for treatment of cryoglobulinemia gave us a chance to observe the long-term effects of interferon on cryoglobulinemia and chronic hepatitis C remission for biochemical, virologic, and histologic aspects.
|
|
|